Genitourinary Tumor Study Ongoing with Active Screening and Enrollment. MILAN and NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer in immuno-o ...

Alvotech and Advanz Pharma have previously entered into partnership agreements for biosimilar candidates to more than ten reference biologics. The companies expect to launch their first biosimilars in ...

The man who inspired the multiple award-winning movie “Jerry Maguire” meets the pioneering stem cell scientist who is ...

PhenQ, the strongest appetite suppressant over the counter (OTC), has officially launched in the United States and ...

Erdem Hospital in Istanbul has announced the launch of a new pre-operative education program tailored specifically for ...

The agreement, signed during CPHI China 2025, represents a high-level partnership between two influential players in their ...

The randomized, placebo-controlled trial is evaluating the safety and efficacy of three dose levels of RPN-001 in men with low testosterone and impaired semen quality. The study plans to enroll ...

Rinri Therapeutics, a world leading company focused on transforming sensorineural hearing loss (SNHL) with regenerative cell therapy, is pleased to announce the approval of its Clinical Trial ...

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which ...

The Company expects additional tranches of the Offering to close on or before July 15, 2025.

The gross proceeds from the Offering are approximately $19 million, before deducting placement agent fees and other estimated offering expenses. The Company intends to use the net proceeds from the ...

VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (the “ Company ”) announces that it will apply to the TSX Venture Exchange (the “ Exchange ”) to ...